HERALD of North-Western State Medical University named after I.I. Mechnikov
https://journals.eco-vector.com/vszgmu
<p>Рeer-review medical academic journal.<strong><br /></strong>Founded in 2009<br /><strong>Editor-in-Cheif</strong>: <a href="https://journals.eco-vector.com/vszgmu/about/editorialTeamBio/1329" target="_blank" rel="noopener">Vadim .I. Mazurov</a></p> <p><strong>Founders</strong>: Eco-Vector LLC, I.I. Mechnikov North-Western State Medical University</p> <p><strong>Publisher:</strong> Eco-Vector LLC<br /><br /></p>
Eco-Vector
ru-RU
HERALD of North-Western State Medical University named after I.I. Mechnikov
2618-7116
<p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the journal exclusive license to first publication.</li> <li>Authors are able to distribute the manuscript and/or the article in accordance with Self-Archiving policy of the journal (<a href="/vszgmu/about/editorialPolicies#authorSelfArchivePolicy" target="_blank" rel="noopener">see details</a>).</li> <li>The manuscript can be accepted for publication only by decision of the Editor-in-Chief and the Editorial board of the journal in accordance with the Manuscript stelection policy of the journal (<a href="/vszgmu/about/editorialPolicies#peerReviewProcess" target="_blank" rel="noopener">see details</a>).</li> <li>Published Article will be distributed in print and electronic version an will be available under subscription with Delayed Open Access or in Immediate Open Access under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ru" target="_blank" rel="noopener">CC BY-NC-ND 4.0</a>). The access model depends on the publisher's decision or is determined by a separate Open Access publishing agreement with the authors.</li> </ol> <p>An exclusive license for publication granted by authors allows the publisher to use the article in the following ways:</p> <ul> <li>Reproduction of the Article or its sections or parts, as well as the metadata of the Article in any languages, in any material form, including on paper and electronic media, as a separate work in the journal and/or databases (local or in the Internet) of the publisher and/or other persons, at the discretion of the publisher;</li> <li>Distribution of the Article or its sections or parts, as well as the metadata of the Article in any languages, on any medium as part of the journal and/or databases of the publisher or other persons, at the discretion of the publisher, or as an independent work around the world whether on Open-Access terms or for a fee without remuneration to the Author;</li> <li>Making the Article or any of its sections or parts, as well as the Article’s metadata in any languages, publicly available in such a way that any person can access the Article from any place, including via the Internet, and at any time of their own choosing;</li> <li>Granting permission/s for the use of the Article or its sections or parts, as well as its metadata in any languages, to third parties with notice to the Author made by posting relevant information on the journal’s website, without paying remuneration to the Author;</li> <li>Processing the Article (i.e., editing, correcting, annotating, tagging, translating to any languages, typesetting) and using the revised (translated) Article in the aforementioned ways.</li> </ul> <p>Other rights not directly transferred to the publisher under this License Agreement, including patent rights to any process, method etc., described by the Authors in the manuscript, as well as trademark rights, are reserved for the Authors.</p> <p>All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical <strong>'HERALD of North-Western State Medical University named after I.I. Mechnikov'</strong>.</p> <p>- <a href="/files/journals/20/doc/Copyrightagreement_final_eng_exclusive_v.2022.09.29.pdf" target="_blank" rel="noopener">DOWNLOAD</a> the print-version of the License Agreement.</p> <div><details open="open"> <summary><strong>READ the details online</strong> (tap to see in details)</summary> <p><strong>Author’s license agreement (public offer) on the publication of an article in a scholarly journal </strong><br /><strong>“HERALD of North-Western State Medical University named after I.I. Mechnikov”</strong></p> <p>Eco-Vector, represented by its CEO Evgeniy Schepin and acting on the basis of the Charter (hereinafter referred to as the Publisher), on the one hand, offers an indefinite circle of persons (hereinafter referred to as the Author), and on the other hand, hereinafter jointly referred to as the Parties, to execute this agreement (hereinafter referred to as the Agreement) on the publication of scientific article (hereinafter referred to as the Article) in a scholarly journal <strong>“HERALD of North-Western State Medical University named after I.I. Mechnikov”</strong> (further-the Journal) in accordance with the conditions stated below.</p> <p> </p> <p><strong>I. General Provisions</strong></p> <ol> <li>This Agreement, in accordance with clause 2 of Article 437 of the Civil Code of the Russian Federation, is a public offer (hereinafter referred to as the Offer) requiring full and unconditional acceptance (Acceptance), which, in accordance with Article 438 of the Civil Code of the Russian Federation, means the sending by the Author of his/her materials by way of uploading the same to the online electronic system designed to accept manuscripts for consideration, and subsequently posted in the corresponding section of the Journal’s website on the Internet information and telecommunications network (hereinafter referred to as the Internet).</li> <li>In accordance with the current legislation of the Russian Federation regarding the observance of copyright on electronic information resources, all materials found in a website, including submitted and published in electronic journals, may not be reproduced in whole or in part in any form (electronic or printed) without the prior written permission of the Publisher. Prior permission can be given by publishing an article in the open access with Creative Commons license. The journal requires license users to reference the original source, i.e., the publication, if the Author permits use of the public materials in the context of other documents.</li> </ol> <p> </p> <p><strong>II. Terms used in the Agreement</strong></p> <ol> <li>“Author” refers to an individual (or individuals) whose creative work has led to the creation of the manuscript of a scientific Article, or to a representative of these persons.</li> <li>“Manuscript” is the result of intellectual activity in the form of a scientific work containing text, graphic and numerical data, audiovisual information, program code and other elements submitted by the Author for publication in the Journal; it is also the mean “a draft of an Article submitted by the Author to be published in the Journal”.</li> <li>“Offer” is the current agreement (an offer to the author for the publication of an Article in the Journal).</li> <li>“Publication” is the process of placement of an Article in the Journal.</li> <li>“Article” is the manuscript that has been published in the Journal (after successful selection, editing, type-setting, copyediting, proofreading, translation).</li> <li>“Acceptance of the offer” refers to the full and unconditional acceptance of the offer on the terms specified in paragraph 3 of this agreement (the Author accepts offer by submitting a Manuscript to the Publisher via the online electronic submission system on the Journal’s Internet website).</li> <li>“Journal” is a scientific peer-reviewed periodical registered as a mass media entity in the Roskomnadzor register of the Russian Federation and ISSN-center.</li> <li>“Submission” is an electronic appeal of the Author to the Publisher for the publication of an Article in the Journal by uploading the manuscript and accompanying materials to the online electronic submission system on the Journal’s Internet website).</li> <li>“Publisher” refers to Eco-Vector, which is the Publisher of the journal.</li> <li>Article metadata includes the information that are intended for inclusion in International Scientific Databases and search engines, namely the following: <ul> <li>title of the Article;</li> <li>information about each of the Authors (surname and first name; patronymic; place of work with the postal address indicated, contact information (e-mail));</li> <li>abstract;</li> <li>keywords;</li> <li>thematic rubricator: UDC (Universal Decimal Classification) or other library and bibliographic classification and subject indexes;</li> <li>list of references.</li> </ul> </li> <li>“Editorial board” is the creative team that prepares the journal for publication.</li> <li>“Parties” refers to the Author and the Publisher.</li> <li>“Author Guidelines” are the requirements for Articles published in the Journal, posted in the “For authors” section of the Journal’s Internet website.</li> </ol> <p> </p> <p><strong>III. Subject of the Agreement (Offer)</strong></p> <ol> <li>Under this agreement, the Author grants the Publisher, free of charge for the entire period of validity in accordance with the legislation of the Russian Federation, an exclusive license to use the Article created by the former for publication in the Journal, as well as the rights to use the article in the following ways: <ul> <li>Reproduction of the Article or its sections or parts, as well as the metadata of the Article in any languages, in any material form, including on paper and electronic media, as a separate work in Journals and/or databases (local or in the Internet) of the Publisher and/or other persons, at the discretion of the Publisher;</li> <li>Distribution of the Article or its sections or parts, as well as the metadata of the Article in any languages, on any medium as part of the Journal and/or databases of the Publisher or other persons, at the discretion of the Publisher, or as an independent work around the world whether on Open-Access terms or for a fee without remuneration to the Author;</li> <li>Making the Article or any of its sections or parts, as well as the Article’s metadata in any languages, publicly available in such a way that any person can access the Article from any place, including via the Internet, and at any time of their own choosing;</li> <li>Granting permission/s for the use of the Article or its sections or parts, as well as its metadata in any languages, to third parties with notice to the Author made by posting relevant information on the Journal’s website, without paying remuneration to the Author;</li> <li>Processing the Article (i.e., editing, correcting, annotating, tagging, translating to any languages, typesetting) and using the revised (translated) Article in the aforementioned ways.</li> </ul> </li> <li>Other rights not directly transferred to the Publisher under this Agreement, including patent rights to any process, method etc., described by the Author in the Article, as well as trademark rights, are reserved for the Author.</li> <li>The territory where the rights to the Article are allowed to be used is the whole world.</li> <li>The validity of this Agreement commences only if the manuscript of the Article is accepted for publication in the Journal and only from the moment of sending a notification of acceptance of the Article for publication to the Author from the official e-mail of the Journal.</li> <li>The rights are granted by the Author to the Publisher free of charge; the publication of the Article in the Journal does not entail any financial deductions to the Author.</li> <li>If the Publisher decides to reject the Submission or refuse to publish the Article in the Journal (i.e., retraction of the published Article), this Agreement becomes invalid. The decision to refuse publication will be sent to the Author at the e-mail address specified in the Submission.</li> </ol> <p> </p> <p><strong>IV. Rights and Duties of the Parties</strong></p> <ol> <li>The Author guarantees that: <ul> <li>s/he holds the copyright the exclusive rights to the materials submitted to the Publisher as part of the manuscript of the Article;</li> <li>the rights granted to the Publisher under this agreement have not been previously transferred and will not be transferred to third parties in the future during the duration of the Agreement;</li> <li>the manuscript contains all references to the cited authors and/or publications (materials) provided for under the current copyright legislation;</li> <li>the Author has obtained all the necessary permissions for all information and other materials s/he holds no copyright to and that are used in the manuscript of the Article;</li> <li>the Article manuscript contains only materials permitted to be published in the open press in accordance with the current legislative acts of the Russian Federation, and its publication and distribution will not lead to the disclosure of secret (confidential) information (including state secrets);</li> <li>the Author has informed co-authors about the terms of this Agreement and has received their consent to execute this Agreement under the terms provided for in the Agreement.</li> </ul> </li> <li>The Author carries certain obligations under the terms of the Agreement: <ul> <li>s/he should prepare and submit the manuscript of the Article in accordance with the Author Guidelines posted on the Journal’s website;</li> <li>the Author should not use an electronic copy of the Article for commercial purposes and in other journal publications without the consent of the Publisher;</li> </ul> </li> <li>in the process of preparing a manuscript for publication, the Author is obligated to undertake the following: <ul> <li>make corrections to the text of the manuscript that have been marked by the peer-reviewers and accepted by the editorial board, and/or as necessary, upon the request of the Publisher and the editorial board, finalize the manuscript of the Article;</li> <li>revising and proofreading the manuscript of the Article in accordance with the editorial recommendations;</li> <li>suggest only the minimum of corrections to the type-setted (layout) Article.</li> </ul> </li> <li>The Author has the following rights and duties: <ul> <li>Use preprint or prior-to publication versions of an unpublished Article in the form and content accepted by the Publisher for publication in the Journal. Such prior-to-publish versions can be placed as electronic files on the personal websites of the Author (co-authors) or on the protected external websites of the employers of the Author; however, the Author cannot use the unpublished version(s) for commercial sale or for systematic external distribution by a third party (i.e., post on social media). The author or co-authors must, in turn, carry out certain duties, namely: <ul> <li>include the following warning in the prior-to-publish version: “This is prior-to-publish version of the article accepted for publication in (Journal’s name), © Eco-Vector (year)”;</li> <li>provide the corresponding electronic link to the Publisher’s website at <a href="https://journals.eco-vector.com/">https://journals.eco-vector.com/</a> and/or via the DOI.</li> </ul> </li> <li>Copy or transfer a copy of the published Article in whole or in part to colleagues free of charge for their personal or professional use, for the promotion of academic or scientific research, or for informational purposes of the Author’s employer.</li> <li>Use materials from a published Article in a book written by one of the co-authors.</li> <li>Use figures, tables and text excerpts from the Article for his or her (or co-authors’) own training purposes, or to include them in other published works in printed or electronic format by a third party, or to submit them in electronic format on an internal computer network, or on the public website of the Author (co-authors) or his/her employer.</li> <li>Include the Article in educational collections for use in the classroom, either for free distribution to the Author’s (co-authors’) students or in electronic format on a local server for access by students as part of the training course, as well as for internal training programs at the institution of the Author’s employer.</li> </ul> </li> <li>The Publisher, for its part, is obliged to: <ul> <li>publish the Author’s article in the Journal in printed and electronic form in accordance with the terms of this Agreement;</li> <li>if necessary, as so decided by the Journal’s editorial board, provide the Author with the proofreading of the manuscript and make a reasonable editing;</li> <li>provide to the Author the unlimited access to the final electronic version of the published Article (Version of Record) through the online electronic submission system on the Journal’s Internet website;</li> <li>comply with the Author’s rights as provided for by the current legislation, as well as protect them and take all necessary measures to prevent copyright infringement by third parties.</li> </ul> </li> <li>The Publisher has a right to: <ul> <li>conduct an expert evaluation of the manuscript (peer-reviewing and editorial evaluation) and invite the Author to make the necessary changes (revisions) to the manuscript;</li> <li>provide editing, copyediting, type-setting, proofreading, tagging, indexation and translation of the Article’s manuscript without altering the main content;</li> <li>in any subsequent authorized use by the Author (and/or other persons) of the Journal and/or Article (including any separate part or fragment thereof), require that a link to the Journal, Publisher, Author or other copyright holders, the title of the Article, the Journal’s volume/issue, and the year of publication be specified in the Journal;</li> <li>post preliminary and/or advertising information about the upcoming publication of the Article in the media and other information sources;</li> <li>make changes to the offer in accordance with the procedure established by the offer.</li> </ul> </li> <li>The editorial board of the Journal, headed by the editor-in-chief, has the exclusive rights to select and/or reject materials sent to the Journal editorial office for publications purposes. The manuscript sent by the Author to the Journal editorial office is not subject to return. The editorial board of the Journal does not enter into correspondence about rejection of submissions.</li> <li>In all cases not stipulated and not provided for in this agreement, the parties are obliged to be guided by the relevant current laws of the Russian Federation.</li> </ol> <p> </p> <p><strong>V. Acceptance of the Offer and Execution of the Agreement. Terms of the Agreement</strong></p> <ol> <li>The Author accepts the Offer by submitting the manuscript on the Article to the Publisher through the electronic manuscript submission system on the Journal's Internet website.</li> <li>Acceptance of the offer by the author creates an Agreement in writing (Articles 438 and 1286.1 of the Civil Code of the Russian Federation) on the terms of the offer.</li> <li>This Agreement is valid for the duration of the exclusive rights to the Article.</li> <li>When transferring (alienating) the exclusive right to the Article by the Author to a third party, this Agreement does not terminate.</li> </ol> <p> </p> <p><strong>VI. Procedure for changing and terminating the Agreement</strong></p> <ol> <li>The Publisher has the right to unilaterally change the terms of this Agreement, in advance, at least 10 (ten) calendar days before the entry into force of the intended relevant changes, but with notice to the Author through the Journal’s website or by e-mail to the Author’s e-mail address specified in the Author’s Submission. The changes will take effect from the date specified in the relevant notification.</li> <li>If the Author rejects the changes to the terms of this Agreement, s/he has the right to notify the Publisher by sending a written notification through the online manuscripts submission system, making sure that the same is sent to the official e-mail address of the editorial office.</li> <li>This Agreement may be terminated prematurely, either by agreement of the parties at any time, or on other grounds provided for in this Agreement.</li> <li>The Author has the right to unilaterally withdraw from the execution of this Agreement by sending the Publisher a corresponding notification in writing at least 60 (sixty) calendar days in advance before the expected date of publication of the Article in the Journal.</li> <li>Termination of the Agreement for any reason does not release the parties from liability for any violation of the terms of the Agreement that occurred during the validity period.</li> </ol> <p> </p> <p><strong>VII. Responsibility</strong></p> <ol> <li>The parties are responsible for non-fulfillment or improper fulfillment of their obligations under the Agreement in accordance with the current relevant legislation of the Russian Federation.</li> <li>All information provided by the Author must be reliable. The Author is expected to provide accurate and complete the information to the Publisher. When using false information received from the Author, the Publisher is not responsible for the negative consequences caused by his actions on the basis of the false information provided.</li> <li>With regard to the content of the Article, the Author is solely responsible for compliance with the requirements of the laws of the Russian Federation pertaining to advertising, copyright and related rights’ protection, protection of trademarks and service marks, and the protection of consumer rights.</li> <li>The Publisher does not bear any responsibility under the agreement: <ul> <li>for any actions that are a direct or indirect result of Author’s illegal actions;</li> <li>for any loss incurred by the Author, regardless of whether the Publisher could have foreseen the possibility of such losses or not.</li> </ul> </li> <li>The Publisher is released from liability for violation of the terms of the Agreement if such violation is caused by force majeure, including actions of state authorities (including the adoption of legal acts), fire, flood, earthquake, other natural disasters, lack of electricity and/or computer network failures, strikes, civil unrest, riots, etc.</li> </ol> <p> </p> <p><strong>VIII. Dispute resolution</strong></p> <ol> <li>Disputes and disagreements will be resolved by the parties through negotiations, and in case of failure to reach an Agreement they will strive to seek resolution in accordance with the current legislation of the Russian Federation.</li> <li>If there are unresolved disagreements, the parties agree to resolve the disputes in court at the jurisdiction covered by the Publisher’s location in accordance with the current legislation of the Russian Federation.</li> </ol> <p> </p> <p><strong>IX. Miscellaneous</strong></p> <ol> <li>All notifications, messages, requests, etc. (with the exception of documents that must be sent as originals in accordance with the laws of the Russian Federation) are considered received by the Author if they were transmitted (sent) by the Publisher through the Journal’s website (including by publication), fax, e-mail based on the address specified in the Submission, and other communication channels. The parties recognize the legal force of notifications, messages, requests, etc., transmitted (sent) by the above methods.</li> <li>In the event of claims against the Publisher related to the violation of the exclusive copyright and other intellectual property rights of third parties when creating an article or in connection with the execution of this Agreement by the Author, as well as in connection with the use of the Article by the Publisher in accordance with the Agreement, the author undertakes: <ul> <li>To immediately take measures to resolve disputes with third parties soon after receiving Publisher’s notification, and if necessary, enter into legal proceedings on the Publisher’s side and take all appropriate actions needed to exclude the Publisher from the list of defendants;</li> <li>To reimburse the publisher for the legal costs incurred and expenses and losses caused by the application of measures to secure the claim and execute a court decision, and the money paid to a third party for the violation of exclusive copyright and other intellectual property rights, as well as other losses incurred by the Publisher in connection with the Author’s non-compliance with the guarantees provided by them under this Agreement.</li> </ul> </li> </ol> <p> </p> <p><strong>X. Legal address and details of the Publisher</strong></p> <ul> <li>Eco-Vector</li> <li>Address: 191186, St. Petersburg, Aptekarsky Pereulok, 3 letter A, room 1N</li> <li>TIN: 7806423692; KPP: 784101001; OGRN: 1099847039907.</li> </ul> </details></div>
-
Impact of urate-lowering therapy on the course of chronic kidney disease in patients with asymptomatic hyperuricemia: a meta-analysis of randomized controlled trials
https://journals.eco-vector.com/vszgmu/article/view/604850
<p>The presented study has been carried out to identify the effect of urate-lowering therapy with xanthine oxidase inhibitors on glomerular filtration rate and serum uric acid in patients with asymptomatic hyperuricemia and chronic kidney disease. A systematic review of randomized controlled trials has been conducted; its results based on meta-analysis has been evaluated.</p> <p>A systematic search and selection of publications in Embase, PubMed, Cochrane Library, and eLibrary databases has been performed. The studied drugs were xanthine oxidase inhibitors: allopurinol and febuxostat. The study considered the following parameters such as efficacy endpoints, namely, glomerular filtration rate and serum uric acid after 3–15 months of follow-up. Clinical and methodological heterogeneity of the included randomized controlled trials has been assessed as well as publication bias and risk of systematic error. Synthesis has been performed using bivariate meta-analysis assessing residual statistical heterogeneity.</p> <p>7 selected randomized controlled trials (1203 patients) have been included in the meta-analysis. This analysis revealed that medication urate-lowering therapy (allopurinol or febuxostat) was associated with higher glomerular filtration rate (+3.0 ml/min/1.73 m2; 95% confidence interval +0.4 to +5.6; p = 0.022) compared with the controls (placebo/no urate-lowering therapy) at 3–15 months of follow-up. Along with this, medication urate-lowering therapy (allopurinol or febuxostat) has been found to result in lower serum uric acid (−3.3 mg/dl; 95% confidence interval −3.8 to −2.8; р < 0.001) compared to the controls (placebo / no urate-lowering therapy) at 3–15 months of follow-up.</p> <p>The results of the meta-analysis have demonstrated a positive role of allopurinol and febuxostat in increasing glomerular filtration rate and decreasing serum uric acid in patients with chronic kidney disease and asymptomatic hyperuricemia. The presented data suggest that therapeutic measures aimed at the elimination of asymptomatic hyperuricemia, including the use of xanthine oxidase inhibitors, may be important in slowing the progression of chronic kidney failure and may be additional factors of nephroprotection.</p>
Vadim I. Mazurov
Sergey A. Sayganov
Anatoly I. Martynov
Roman A. Bashkinov
Inna Z. Gaydukova
Kirill V. Sapozhnikov
Daria G. Tolkacheva
Natalia A. Sableva
Alexandra Yu. Tsinzerling
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
5
18
10.17816/mechnikov604850
-
Enamel and dentin of human teeth. Fatigue strength
https://journals.eco-vector.com/vszgmu/article/view/624120
<p>The article provides a brief overview of the studies regarding changes in the structure and composition of teeth after eruption. The factors of degenerative changes in tooth structures and their relationship with non-carious lesions have been analyzed. The study makes emphasis on the tooth durability and the factors influencing tissue fatigue, explaining increased tissue wear due to local factors. Understanding mechanisms of metabolism of teeth hard tissues is the key to the stability of restorative treatments and occurrence of non-carious tooth lesions. The evolution of views on this problem is noteworthy. The literature review reveals the initial predominance of mechanical actions, abrasion, and mineralization. It is later complemented by a detailed analysis of the influence of destructive stresses and deformation due to mechanical factors. All the leading works of the 2000s are dedicated to analyzing the ultrastructural features of enamel that affect its mechanical characteristics and can explain both the characteristics of the shape and intensity of mechanical tooth wear during the functioning of the stomatognathic system, as well as the durability of the performed restorations. The literature review covers 74 sources over the past 15 years.</p>
Alexey V. Silin
Elena A. Satygo
Alexander T. Maryanovich
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
19
29
10.17816/mechnikov624120
-
Strategy of stage treatment for patients with perforated diverticulitis: first experience
https://journals.eco-vector.com/vszgmu/article/view/601813
<p><strong>BACKGROUND</strong>: The results of surgical treatment of patients with perforative diverticulitis of the colon are still unsatisfactory today. Since the majority of patients undergo Hartmann surgery, the main problem is a large number of stoma patients. Three quarters of them live with a stoma for a long time, which negatively affects their quality of life and increases the cost of treatment.</p> <p><strong>AIM:</strong> The purpose of this research work is to improve the immediate results of treating patients with perforative diverticulitis and peritonitis by using staged surgical tactics.</p> <p><strong>MATERIALS AND METHODS:</strong> The reaserach included 14 patients with perforative diverticulitis Hinchey grade II-III. The average value of the Mannheim peritoneal index is 18.9 ± 6.3 points. At the first stage of surgical treatment, all the patients underwent colon resection with a zone of perforation of the diverticulum and leaving its muffled ends in the abdominal cavity. After lavage and drainage, temporary closure of the anterior abdominal wall was performed. After 24–48 hours, all the patients underwent colon reconstraction.</p> <p><strong>RESULTS:</strong> The average age of the patients was 52.3 ± 12.4 years with 4 women (28.6%) and 10 men (71.4%). The average duration of the first stage was 105.7 ± 27.2 minutes, the second one — 113.2 ± 40.5 minutes. The average hospital-stays were 16.4 ± 7.2 days. There were no anastomosis failures and no lethal outcomes. Complications were noted in 9 patients (64.3%), grade I according to Clavien – Dindo — 83.4%.</p> <p><strong>CONCLUSIONS:</strong> The tactics of early surgical treatment is a promising concept for patients with perforative diverticulitis. It provides rapid elimination of the septic focus during the first surgical operation, assumes early reconstruction of the intestine without increasing the number of complications and mortality, and can be used in patients with peritonitis.</p>
Boris G. Bezmozgin
Evita V. Poryvaeva
Ekaterina A. Pirozhkova
Oleg V. Babkov
Ivan P. Yastrebov
Ildar M. Batyrshin
Dmitry A. Surov
Andrey E. Demko
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
31
40
10.17816/mechnikov601813
-
Factors of stroke misdiagnosis at the onset of myastenia gravis
https://journals.eco-vector.com/vszgmu/article/view/492276
<p><strong>BACKGROUND</strong>: Myasthenia gravis is a rare autoimmune disease,which is difficult to diagnose mainly in the initial stages, when there are single symptoms of the disease or an atypical course. Diagnostic errors are associated with the fact that myasthenia gravis and other diseases of the nervous system have similar symptoms. The most common misdiagnosis in the onset of myasthenia gravis is a stroke. However, the reasons for a false diagnosis remain unspecified and poorly understood.</p> <p><strong>AIM:</strong> To determine the factors leading to misdiagnosis of a stroke in the onset of myasthenia gravis.</p> <p><strong>MATERIALS AND METHODS:</strong> 133 patients diagnosed with myasthenia gravis were divided into two groups. Patients with misdiagnosed stroke at the onset of myasthenia gravis formed the first group, the rest of the patients – the second group. A comparative assessment was performed according to the age of myasthenia onset, the clinical variant of the onset, primary symptoms, the duration of diagnosis, and the severity of the disease at the time of the correct diagnosis, with the percentage of misdiagnosis calculation.</p> <p><strong>RESULTS:</strong> Stroke as misdiagnosis was established more often than others (in 23% of all cases and in 44% of incorrect diagnoses). In the 1st group, complaints of dysarthria and dysphagia were significantly higher, myasthenia gravis began acutely more often, the age of myasthenia onset in patients of the 1st group was statistically higher than in the 2nd. There was no difference between the groups in terms of diagnosis duration, the disease severity, and the history of previous stroke.</p> <p><strong>CONCLUSIONS:</strong> Factors leading to stroke misdiagnosis at the onset of myasthenia are advanced age and acute onset with bulbar disorders.</p>
Ailer R. Alibekov
Vitaliy V. Goldobin
Hosiddin F. Yuldashev
Elena G. Klocheva
Irina A. Lubenets
Aruzhan Zh. Nurmakhanbetova
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
41
50
10.17816/mechnikov492276
-
The influence of comorbid diseases on the profiles of signaling biomarkers (macrophage-derived chemokine, interferon-γ-induced protein 10 kD, soluble CD40 ligand, vascular endothelial growth factor) and severity in patients with COVID-19: clinical studies
https://journals.eco-vector.com/vszgmu/article/view/624558
<p><strong>BACKGROUND</strong>: Analysis of the effect of comorbid diseases on the concentration of biomarkers will help to deepen the understanding of the pathogenetic mechanisms of the impact of comorbid diseases on the course of COVID-19 and adjust prognostic models for its therapy.</p> <p><strong>AIM:</strong> To study the impact of comorbid diseases on the severity and outcomes of COVID-19. In addition, an analysis of the levels of macrophage-derived chemokine, interferon-γ-induced protein 10 kD, soluble CD40 ligand, vascular endothelial growth factor has been carried out in 472 patients with COVID-19, depending on the presence of various forms of comorbid pathology.</p> <p><strong>MATERIALS AND METHODS:</strong> To study the concentration of biomarkers an analysis has been conducted in a group of 1648 patients with confirmed COVID-19. The study assessed intergroup differences (disease outcome/severity of disease) in the general group (1648 patients) and in the group of patients without comorbidity (343 patients) — Charlson index less than 2 points. 472 medical histories of patients with COVID-19 have been analyzed, including with certain concentrations of the studied biomarkers and comorbid pathology included in the Charlson Index. For comparison, two samples have been formed: an experimental group consisting of patients with COVID-19 and the presence of a certain comorbid disease and a control group consisting of patients suffering from COVID-19 without a specified comorbid disease.</p> <p><strong>RESULTS:</strong> For the first time, data has been obtained indicating that patients with COVID-19 have comorbid conditions with the levels of the studied biomarkers differing significantly from the indicators of the control group. Thus, in patients with arterial hypertension (I10–I15 according to the International Classification of Diseases, 10th revision), chronic heart failure (I50.0), diseases of the vascular system (I70–I79), cerebrovascular diseases (I60–I69), chronic kidney disease (N17–N19), the level of the macrophage-derived chemokine biomarker was significantly lower than in the patients without these diseases. At the same time, in the COVID-19 patients with respiratory diseases (J40–J47), the levels of interferon-γ-induced protein 10 kD and vascular endothelial growth factor were significantly lower than in the patients who did not have lung diseases.</p> <p><strong>CONCLUSIONS:</strong> The study findings obtained have confirmed the role of signaling biomarkers in the development of severe forms and death in patients with COVID-19. Significant influence of comorbid pathology on the course of the new coronavirus infection has been shown.</p>
Anna Yu. Anisenkova
Vadim I. Mazurov
Svetlana V. Apalko
Oleg S. Popov
Natalya N. Sushentseva
Olga P. Mamaeva
Sergei V. Mosenko
Andrey M. Sarana
Sergey G. Shcherbak
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
51
63
10.17816/mechnikov624558
-
Surgical aspects of the treatment of a patient with actinomycosis of the colon complicated by the formation of a colovesical fistula
https://journals.eco-vector.com/vszgmu/article/view/606683
<p>Actinomycosis is a chronic bacterial infection caused by bacteria from the Actinomycetaceae family. The causes of abdominal actinomycosis are usually destructive appendicitis, prolonged presence of an intrauterine contraceptive or perforation of the colon. Of the internal organs, the left colon and sigmoid colon are most often affected, which often leads to surgical complications. At the same time, diagnosis is significantly difficult due to the nonspecific nature of the clinical presentation, which is similar to that of oncological diseases, and verification of the process is possible only with microscopic examination in a specialized institution.</p> <p>A clinical case demonstrating the difficulties of diagnosis and treatment of widespread abdominal actinomycosis complicated by the development of a colovesical fistula is presented.</p>
Badri V. Sigua
Alexey A. Kurkov
Elguja L. Lataria
Olga P. Kozlova
Dmitrii V. Gurzhiy
Sergey A. Vinnichuk
Alexey L. Efimov
Gleb V. Chizhov
Andrey A. Khvatov
Viacheslav P. Zemlianoi
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
65
72
10.17816/mechnikov606683
-
Pulmonary artery thrombosis. Clinical cases
https://journals.eco-vector.com/vszgmu/article/view/623001
<p>Accumulating evidence supports the need to consider pulmonary artery thrombosis the separate thrombotic complication, which requires its own treatment algorithms.</p> <p>The aim of the work is to demonstrate the pulmonary artery thrombosis clinical aspects and the effect of the standard thrombotic prophylactic algorithms with clinical examples.</p> <p>Clinical cases of patients with pulmonary artery thrombosis are presented. Pulmonary artery thrombosis is considered to be the thrombotic obstruction of the pulmonary artery branches in the absence of venous and cardiac chambers thrombosis.</p> <p>Patient S. with COVID-19 and 75% of lung involvement was treated in the accordance with the actual COVID-19 treatment recommendations. Enoxaparin sodium 6000 IE once a day followed by the increasing dosage of 8000 IE twice a day was used. To prevent exacerbation tocilizumab was infused, and systemic thrombolytic therapy was performed. On the 6th day after systemic thrombolytic therapy patient died. Examination revealed thrombi in the pulmonary artery branches.</p> <p>Patient P. with continued growth of cerebral left frontoparietal region glioblastoma was hospitalized. Surgical tumor removal was performed a year ago. Conservative therapy, dexamethasone injections and anticoagulant prophylaxis (enoxaparin sodium 4000 IE once a day) were prescribed. After the patient death thrombi were found in the pulmonary artery segmental branches.</p> <p>Outpatient D. had a history of four episodes of dyspnea during the acute respiratory diseases. Computed tomography performed at the time of the third and fourth episodes revealed thrombi in the pulmonary artery segmental branches. The fourth episode occured despite anticoagulant prophylaxis with rivaroxaban (10 mg once a day). Patient was recommended to switch to low molecular weight heparins in case of any disease. There have been no recurrent episodes over the past 8 months.</p> <p>Distinctive features of pulmonary artery thrombosis pathogenesis determine the development of the complication despite anticoagulant prophylaxis. Preventive effect of anti-inflammatory drugs on the pulmonary artery thrombosis development has not been demonstrated.</p>
Olga Ya. Porembskaya
Sergey N. Tsaplin
Kirill V. Lobastov
Victoria A. Ilina
Viacheslav N. Kravchuk
Sergey A. Sayganov
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
73
79
10.17816/mechnikov623001
-
Retroperitoneal synovial sarcoma
https://journals.eco-vector.com/vszgmu/article/view/624440
<p>Synovial sarcoma of the retroperitoneum is a rare and aggressive tumor. In some cases, differential diagnosis between retroperitoneal sarcoma and adrenocortical cancer is difficult due to the similar clinical and intrascopic manifestations of these neoplasms. The final diagnosis is established based on the results of histological, immunohistochemical and genetic studies. The most important step in the treatment of synovial sarcoma is complete removal of the tumor. However, despite the radical nature of the intervention, the incidence of local relapse and metastasis remains high.</p> <p><strong>AIM</strong><strong>:</strong> to conduct a retrospective analysis of the parameters of operated patients with synovial sarcoma of the retroperitoneum.</p> <p>This study is aimed at studying the results of examination and surgical treatment of patients with synovial sarcoma of the retroperitoneal space who were hospitalized in the E.E. Eichwald Clinic surgical department of the North-Western State Medical University named after. I.I. Mechnikov.</p> <p>The patients were assessed for hormonal status using an immunoassay to determine the levels of adrenocorticotropic hormone, cortisol, aldosterone, renin, normetanephrine and metanephrine in the blood, and a dexamethasone suppression test has been performed at a dose of 1 mg. High-performance liquid chromatography has determined 6 glucocorticoids in the blood serum: cortisol, cortisone, corticosterone, 11-deoxycorticosterone, 11-dehydrocorticosterone, 11-deoxycortisol. The urine steroid profile was studied in all the patients using gas chromatography-mass spectrometry. All the patients underwent computed tomography of the abdominal organs and retroperitoneal space with contrast, morphological and immunohistochemical examination of the removed material. The material was fixed in 10% neutral buffered formalin. The pieces were then subjected to standard wiring followed by embedding in paraffin. Sections 2–3 microns thick were prepared from the resulting blocks and stained with hematoxylin and eosin. Immunohistochemical studies were performed on paraffin sections. A panel of monoclonal antibodies was used: protein S-100 (poly), pancytokeratin (AE1/AE3), EMA, cytokeratin-8, -18, chromogranin A, synaptophysin, α-inhibin, SOX-10, CD99, TLE-1, bcl- 2, GATA-3. Postoperative outcomes and follow-up were assessed according to the information in the medical records and data obtained from a telephone conversation with each patient. Statistical processing of the results has not been out due to rare cases of the disease.</p>
Aleksandr A. Lisitsyn
Vyacheslav P. Zemlyanoy
Inna Е. Kotkas
Irina A. Bekhtereva
Copyright (c) 2024 Eco-Vector
2024-01-13
2024-01-13
15 4
81
88
10.17816/mechnikov624440